AU2011361921B2 - Formulation comprising phenylaminopyrimidine derivative as active agent - Google Patents

Formulation comprising phenylaminopyrimidine derivative as active agent Download PDF

Info

Publication number
AU2011361921B2
AU2011361921B2 AU2011361921A AU2011361921A AU2011361921B2 AU 2011361921 B2 AU2011361921 B2 AU 2011361921B2 AU 2011361921 A AU2011361921 A AU 2011361921A AU 2011361921 A AU2011361921 A AU 2011361921A AU 2011361921 B2 AU2011361921 B2 AU 2011361921B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
weight
composition according
total weight
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011361921A
Other languages
English (en)
Other versions
AU2011361921A1 (en
AU2011361921A2 (en
Inventor
Kali Satya Bhujanga Rao Adibhatla
Venkata Satyanarayana APPADWEDULA
Venkaiah Chowdary Nannapaneni
Durga Maheswari Parvataneni
Siddhartha YEDLURI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011361921(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of AU2011361921A1 publication Critical patent/AU2011361921A1/en
Publication of AU2011361921A2 publication Critical patent/AU2011361921A2/en
Application granted granted Critical
Publication of AU2011361921B2 publication Critical patent/AU2011361921B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2011361921A 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent Ceased AU2011361921B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
GB1103860.1 2011-03-07
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (3)

Publication Number Publication Date
AU2011361921A1 AU2011361921A1 (en) 2013-09-26
AU2011361921A2 AU2011361921A2 (en) 2014-10-30
AU2011361921B2 true AU2011361921B2 (en) 2016-06-09

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011361921A Ceased AU2011361921B2 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Country Status (33)

Country Link
US (1) US9895367B2 (cg-RX-API-DMAC10.html)
EP (1) EP2683381B1 (cg-RX-API-DMAC10.html)
JP (1) JP5788534B2 (cg-RX-API-DMAC10.html)
KR (1) KR101767296B1 (cg-RX-API-DMAC10.html)
CN (1) CN103561742B (cg-RX-API-DMAC10.html)
AP (1) AP4076A (cg-RX-API-DMAC10.html)
AU (1) AU2011361921B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013022930A2 (cg-RX-API-DMAC10.html)
CA (1) CA2829015C (cg-RX-API-DMAC10.html)
CO (1) CO6811851A2 (cg-RX-API-DMAC10.html)
CY (1) CY1116968T1 (cg-RX-API-DMAC10.html)
DK (1) DK2683381T3 (cg-RX-API-DMAC10.html)
EA (1) EA024610B1 (cg-RX-API-DMAC10.html)
ES (1) ES2554927T3 (cg-RX-API-DMAC10.html)
GB (1) GB2488788B (cg-RX-API-DMAC10.html)
GE (1) GEP20156410B (cg-RX-API-DMAC10.html)
HR (1) HRP20151382T1 (cg-RX-API-DMAC10.html)
HU (1) HUE025562T2 (cg-RX-API-DMAC10.html)
IL (1) IL228218A (cg-RX-API-DMAC10.html)
MA (1) MA35088B1 (cg-RX-API-DMAC10.html)
MX (1) MX339130B (cg-RX-API-DMAC10.html)
MY (1) MY158693A (cg-RX-API-DMAC10.html)
NZ (1) NZ614903A (cg-RX-API-DMAC10.html)
PH (1) PH12013501844A1 (cg-RX-API-DMAC10.html)
PL (1) PL2683381T3 (cg-RX-API-DMAC10.html)
PT (1) PT2683381E (cg-RX-API-DMAC10.html)
RS (1) RS54420B1 (cg-RX-API-DMAC10.html)
SG (1) SG193349A1 (cg-RX-API-DMAC10.html)
SI (1) SI2683381T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201500235B (cg-RX-API-DMAC10.html)
UA (1) UA111074C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012120328A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201306643B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201805142RA (en) 2015-12-18 2018-07-30 Natco Pharma Ltd Pharmaceutical compositions comprising phenylaminopyrimidine derivative
EP3397242B1 (en) * 2015-12-29 2021-02-03 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
EA202092131A1 (ru) * 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
JP2022523704A (ja) * 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027795A1 (en) * 2004-09-09 2006-03-16 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
WO2008051597A1 (en) * 2006-10-26 2008-05-02 Sicor Inc. Process for the preparation of imatinib
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
MX2009011479A (es) * 2007-04-30 2010-02-01 Intezyne Technologies Inc Micelas de copolimero de bloque hibrido con estereoquimica mezclada para encapsulacion de hidrofobos.
US8067422B2 (en) * 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
EP2265599B1 (en) 2008-03-04 2013-11-20 Natco Pharma Limited Crystal form of phenylaminopyrimidine derivative
JP5791500B2 (ja) * 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027795A1 (en) * 2004-09-09 2006-03-16 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase

Also Published As

Publication number Publication date
GB2488788A (en) 2012-09-12
ZA201306643B (en) 2014-11-26
EP2683381B1 (en) 2015-09-16
SI2683381T1 (sl) 2016-01-29
KR101767296B1 (ko) 2017-08-10
JP2014507463A (ja) 2014-03-27
US20130338180A1 (en) 2013-12-19
GEP20156410B (en) 2015-12-10
PT2683381E (pt) 2015-11-02
IL228218A (en) 2016-06-30
JP5788534B2 (ja) 2015-09-30
MX339130B (es) 2016-05-13
ES2554927T3 (es) 2015-12-28
BR112013022930A2 (pt) 2016-12-06
WO2012120328A1 (en) 2012-09-13
AU2011361921A1 (en) 2013-09-26
EA201391280A1 (ru) 2014-02-28
EA024610B1 (ru) 2016-10-31
RS54420B1 (sr) 2016-04-28
PL2683381T3 (pl) 2016-06-30
MA35088B1 (fr) 2014-05-02
CN103561742A (zh) 2014-02-05
AU2011361921A2 (en) 2014-10-30
AP4076A (en) 2017-03-23
CA2829015C (en) 2018-01-02
DK2683381T3 (en) 2015-12-21
CY1116968T1 (el) 2017-04-05
GB201103860D0 (en) 2011-04-20
SMT201500235B (it) 2015-10-30
PH12013501844A1 (en) 2015-10-23
CA2829015A1 (en) 2012-09-13
UA111074C2 (uk) 2016-03-25
US9895367B2 (en) 2018-02-20
HUE025562T2 (en) 2016-03-29
CO6811851A2 (es) 2013-12-16
GB2488788B (en) 2013-07-10
SG193349A1 (en) 2013-10-30
AP2013007128A0 (en) 2013-09-30
NZ614903A (en) 2014-08-29
CN103561742B (zh) 2016-04-27
EP2683381A1 (en) 2014-01-15
HRP20151382T1 (hr) 2016-02-12
MY158693A (en) 2016-11-15
KR20140016926A (ko) 2014-02-10
MX2013010160A (es) 2013-12-06

Similar Documents

Publication Publication Date Title
CA2829015C (en) Formulation comprising phenylaminopyrimidine derivative as active agent
JP2012111763A (ja) 自然分散性ｎ−ベンゾイルスタウロスポリン組成物
US8486983B2 (en) Self-emulsifying formulations of CETP inhibitors
JP7692366B2 (ja) メチルナルトレキソンの液体経口投与製剤
JP4982378B2 (ja) カンプトテシン誘導体を含む医薬組成物
KR101928589B1 (ko) 알리스포리비르를 포함하는 제약 조성물
JP2010513351A (ja) 酸を含むゼラチンカプセル剤
KR101469953B1 (ko) 포에누모사이드 포함 자가유화 약물전달시스템 조성물 및 이의 제조방법
RU2827066C2 (ru) Композиции жидкой пероральной лекарственной формы метилналтрексона
JP2007520521A (ja) 特定のサブスタンスｐアンタゴニストを含んでなるマイクロエマルジョン製剤
TW200800195A (en) Organic compounds
KR20070018003A (ko) 특정 물질 ｐ 길항제를 포함하는 마이크로에멀젼 제제

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 AUG 2014

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired